400 Women Enroll in National Registry to Track Outcomes of Drug Named in Risperdal Lawsuit Litigation

Published on May 5, 2014 by Laurie Villanueva

Text-Size:A A A+


More than 400 women have now been enrolled in a national pregnancy registry involving the use of a medication involved in Risperdal lawsuit litigation, as well as other atypical antipsychotic drugs, according to Clinical Psychiatry News.

The National Pregnancy Registry was created in 2011 to track outcomes of pregnant patients prescribed atypical antipsychotics. Launched by the clinical director of the Women’s Mental Health Center at Massachusetts General Hospital, the registry’s foundation followed research conducted between 2001 and 2007 that found a 2.5 increase in the number of drug scripts written to women 60 days or fewer before they gave birth. Among other things, the study showed 0.72% of women taking Risperdal or another atypical antipsychotic out of 585,615 deliveries occurring over a 6-year period. The rate of major malformations in children born to mothers taking the drugs was also found to be two times greater when compared to a control group, while little difference was found between first and second-generation versions.

Antipsychotic Drug Scripts Increase as Risperdal Gynecomastia Lawsuits Are Filed

The Johnson & Johnson manufactured medication, Risperdal, are given to women suffering from such conditions as depression, schizophrenia and bipolar disorder.

Given the rise in pregnancies aided by atypical antipsychotics, the registry’s creator has stressed the importance of collecting data that measures potential side effects. “Our registry is carefully, prospectively done,” she said. “It’s all done by phone, with two calls during pregnancy and one post-partum.”

The number of Risperdal scripts written to patients in the U.S. has consistently grown over the past few years, however. A drug approved to treat schizophrenia and bipolar disorder, uses for Risperdal in children is prescribed to those with autism, as well as symptoms associated with ADHD.

Individuals exposed to Risperdal have since gone on to file lawsuits over the drug, many of which are now pending in a consolidated litigation established in the Philadelphia Court of Common Pleas. Among other complications included in the litigation involve those alleging Risperdal gynecomastia, a condition categorized by male breast growth. Court records indicate that 350 claims are now pending in Pennsylvania state court.

Filing a Risperdal Lawsuit

Call our Firm now to learn more about Risperdal lawsuits, and whether you are eligible to seek compensation for lost wages, out-of-pocket medical expenses and other damages. Start the process of filing a claim alleging gynecomastia at .